Hubert Kettenberger
Overview
Explore the profile of Hubert Kettenberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Beckmann R, Jensen K, Fenn S, Speck J, Krause K, Meier A, et al.
Nat Commun
. 2021 Jan;
12(1):708.
PMID: 33514724
We report the development of a platform of dual targeting Fab (DutaFab) molecules, which comprise two spatially separated and independent binding sites within the human antibody CDR loops: the so-called...
12.
Waibl F, Fernandez-Quintero M, Kamenik A, Kraml J, Hofer F, Kettenberger H, et al.
Biophys J
. 2020 Nov;
120(1):143-157.
PMID: 33220303
A major challenge in the development of antibody biotherapeutics is their tendency to aggregate. One root cause for aggregation is exposure of hydrophobic surface regions to the solvent. Many current...
13.
Caruso A, Futh M, Alvarez-Sanchez R, Belli S, Diack C, Maass K, et al.
Mol Pharm
. 2019 Dec;
17(2):695-709.
PMID: 31876425
Therapeutic antibodies administered intravitreally are the current standard of care to treat retinal diseases. The ocular half-life () is a key determinant of the duration of target suppression. To support...
14.
Kraft T, Richter W, Emrich T, Knaupp A, Schuster M, Wolfert A, et al.
MAbs
. 2019 Nov;
12(1):1683432.
PMID: 31769731
The pharmacokinetic (PK) properties of therapeutic antibodies directly affect efficacy, dose and dose intervals, application route and tissue penetration. In indications where health-care providers and patients can choose between several...
15.
Schadt S, Hauri S, Lopes F, Edelmann M, Staack R, Villasenor R, et al.
Drug Metab Dispos
. 2019 Nov;
47(12):1443-1456.
PMID: 31748266
For therapeutic proteins, the currently established standard development path generally does not foresee biotransformation studies by default because it is well known that the clearance of therapeutic proteins proceeds via...
16.
Sustmann C, Dickopf S, Regula J, Kettenberger H, Molhoj M, Gassner C, et al.
MAbs
. 2019 Sep;
11(8):1402-1414.
PMID: 31526159
High specificity accompanied with the ability to recruit immune cells has made recombinant therapeutic antibodies an integral part of drug development. Here we present a generic approach to generate two...
17.
Edelmann M, Kettenberger H, Knaupp A, Schlothauer T, Otteneder M
J Labelled Comp Radiopharm
. 2019 Aug;
62(11):751-757.
PMID: 31369163
The number of therapeutic antibodies in research and development as well as their complexity increases from year to year. Novel therapeutic protein formats, such as Fc-fusions, bispecific, or multivalent antibodies,...
18.
Mayer K, Mundigl O, Kettenberger H, Birzele F, Stahl S, Pastan I, et al.
Redox Biol
. 2018 Oct;
20:146-156.
PMID: 30312900
The diphthamide modification of translation elongation factor 2 is highly conserved in eukaryotes and archaebacteria. Nevertheless, cells lacking diphthamide can carry out protein synthesis and are viable. We have analyzed...
19.
Schanzer J, Wartha K, Moessner E, Hosse R, Moser S, Croasdale R, et al.
MAbs
. 2016 Mar;
8(4):811-27.
PMID: 26984378
The epidermal growth factor receptor (EGFR) and the insulin-like growth factor-1 receptor (IGF-1R) play critical roles in tumor growth, providing a strong rationale for the combined inhibition of IGF-1R and...
20.
Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, et al.
MAbs
. 2016 Feb;
8(3):562-73.
PMID: 26864324
Vascular endothelial growth factor (VEGF)-A blockade has been validated clinically as a treatment for human cancers. Angiopoietin-2 (Ang-2) is a key regulator of blood vessel remodeling and maturation. In tumors,...